Financial Comparison: CASI Pharmaceuticals (NASDAQ:CASI) & Praxsyn (OTCMKTS:PXYN)

Praxsyn (OTCMKTS:PXYN) and CASI Pharmaceuticals (NASDAQ:CASI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Risk and Volatility

Praxsyn has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Insider & Institutional Ownership

22.2% of CASI Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Praxsyn and CASI Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Praxsyn	N/A	N/A	N/A
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

Earnings & Valuation

This table compares Praxsyn and CASI Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxsyn	N/A	N/A	N/A	N/A	N/A
CASI Pharmaceuticals	$28.54 million	0.36	-$39.26 million	($3.01)	-0.27

Praxsyn has higher earnings, but lower revenue than CASI Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and price targets for Praxsyn and CASI Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxsyn	0	0	0	0	0.00
CASI Pharmaceuticals	1	0	1	0	2.00

CASI Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 385.44%. Given CASI Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Praxsyn.

Summary

CASI Pharmaceuticals beats Praxsyn on 6 of the 9 factors compared between the two stocks.

About Praxsyn

Praxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers’ compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.